RIVAROXABAN IN COMBINATION WITH ANTIARRHYTHMIC DRUGS DOES NOT INCREASE THE BLEEDING RISKS IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30957-8
Abstract: Rivaroxaban (RIVA) is useful for stroke prevention in atrial fibrillation (AF) patients. Antiarrhythmic drugs (AADs) prevent the recurrence of AF in non-permanent AF (npAF). There are limited data regarding drug-drug interactions between RIVA and AADs.… read more here.
Keywords: atrial fibrillation; non permanent; combination antiarrhythmic; rivaroxaban combination ... See more keywords